title: Infectious dilemma. As hospitals gird against healthcare-associated infections and face CMS' vow not to pay for them after October, they must make some expensive decisions.
abstract: As the October onset of the CMS' decision not to pay for some "never events" approaches, hospitals are faced with a daunting array of products meant to combat healthcare-associated infections. One option is rapid testing for MRSA, which Keith Ramsey, left, says cost his hospital $950,000 in the first year, but it recouped $700,000 from payer reimbursement for testing. He says it was a smart investment.
authors.forename: Shawn
authors.initials: S
authors.lastname: Rhea
mesh_terms: D014487:Centers for Medicare and Medicaid Services, U.S.; D003428:Cross Infection / Q000191:economics / Q000517:prevention & control*; D003659:Decision Making, Organizational; D004469:Economics, Hospital; D012051:Reimbursement Mechanisms / Q000458:organization & administration; D014481:United States